RVL Pharmaceuticals Focuses on Scaling Upneeq as Market Momentum Builds
RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
A New York plastic surgeon explains why he built an in-office recovery suite and how enhanced, wellness-driven post-op care can reshape patient outcomes.
The latest iteration of the multi-application platform adds new pulsed-light features and is approved to treat over 30 indications for skin and hair removal.
The American Academy of Facial Plastic and Reconstructive Surgery is highlighting how energy-based devices are reshaping non-surgical facial rejuvenation in 2025.
The move addresses increased mergers, acquisitions, and regulatory scrutiny in the state's growing med spa and wellness sector.